Evaluation of Short Term Use of Experimental Eye Drops BHVI2, 0.02% Atropine and BHVI2 Plus 0.02% Atropine Eye Drops
Status:
Completed
Trial end date:
2019-06-30
Target enrollment:
Participant gender:
Summary
To assess the one-month ocular effects of nightly application of experimental BHVI2 and 0.02%
atropine eye drops either alone or in combination, in children aged between 6 to 13 years old
with myopia and randomized to use of experimental BHVI2 eye drops, 0.02% atropine eye drops,
experimental BHVI2 plus 0.02% atropine eye drops.